natgillin/translations-raw huggingface dataset:
Der er rapporteret sjældne tilfælde af enterocolitis, herunder colitis, iskæmisk colitis og neutropenisk enterocolitis med en potentielt dødelig udgang (hyppighed ikke kendt). 
Rare cases of enterocolitis, including colitis, ischemic colitis, and neutropenic enterocolitis, have been reported with a potential fatal outcome (frequency not known).Rare occurrences of dehydration have been reported as a consequence of gastrointestinal events including enterocolitis and gastrointestinal perforation.
Neglesygdomme (alvorlig: 2,6 %) 
Dyspnoea (severe: 2.7%)
I kombination med trastuzumab er den anbefalede dosis af docetaxel 100 mg/m2 hver 3. uge med en ugentlig administration af trastuzumab. 
In combination with trastuzumab the recommended dose of docetaxel is 100 mg/m2 every three weeks,
Mængden af alkohol i dette lægemiddel og bivirkningerne ved lægemidlet kan nedsætte evnen til at føre motorkøretøj eller betjene maskiner (se pkt. 
The amount of alcohol in this medicinal product and the side effects of the product may impair the ability to drive or use machines (see sections 4.4 and 4.8).
Det skal du vide, før du begynder at bruge Docetaxel Accord Sådan skal du bruge Docetaxel Accord Bivirkninger 
What Docetaxel Accord is and what it is used for What you need to know before you use Docetaxel Accord How to use Docetaxel Accord Possible side effects
De bivirkninger, som sandsynligvis er relateret til anvendelsen af docetaxel, er set hos: • 1.312 og 121 patienter, som fik henholdsvis 100 mg/m2 og 75 mg/m2 af doceraxel som enkeltstof. 
• 1,312 and 121 patients who received 100 mg/m2 and 75 mg/m2 of docetaxel as a single agent respectively.
Anvend ikke andre docetaxel lægemidler bestående af 2 hætteglas (koncentrat og solvens) sammen med dette lægemiddel, der kun indeholder 1 hætteglas med koncentrat. 
DO NOT use other docetaxel medicinal products consisting of 2 vials (concentrate and solvent) with this medicinal product which contains only 1 vial of concentrate.
Bemærk, at dette sandsynligvis er underestimeret, da docetaxel alene ved en dosis på 100 mg/m2 er kendt for at resultere i neutropeni hos 
Note that this is likely to be an underestimate since docetaxel alone at a dose of 100 mg/m2 is known to result in neutropenia in 97% of patients, 76% grade 4, based on nadir blood counts.
Ved den mediane opfølgningsperiode på 10 år og 5 måneder havde TAC-behandlede patienter 16,5 % lavere risiko for tilbagefald sammenlignet med de patienter, der blev behandlet med FAC (hazard ratio = 0,84; 95 % CI (0,65-1,08); p = 0,1646). 
At the median follow up time of 10 years and 5 months, TAC-treated patients had a 16.5% reduction in the risk of relapse compared to those treated with FAC (hazard ratio = 0.84, 95% CI (0.64-1.08), p=0.1646).
Bland manuelt opløsningen i infusionsposen med vippende bevægelser. 
Mix the infusion bag manually using a rocking motion.
Patienter bør modtage kemostrålingsterapi efter kemoterapi 
Following chemotherapy, patients should receive chemoradiotherapy.
Tabel over bivirkninger ved behandling af prostatakræft med docetaxel 75 mg/m² i kombination med prednison eller prednisolon: 
Tabulated list of adverse reactions in prostate cancer for docetaxel 75 mg/m2 in combination with prednisone or prednisolone
Kirurgisk resektion blev tilladt efter kemoterapi, 
Surgical resection was allowed following chemotherapy, before or after radiotherapy.
Fra et mikrobiologisk synspunkt skal fortynding foretages under kontrollerede og aseptiske forhold og lægemidlet bør anvendes umiddelbart herefter. 
• From a microbiological point of view, dilution must take place in controlled and aseptic conditions and the infusion solution should be used immediately.
• Bland manuelt opløsningen i infusionposen med vippende bevægelser. 
• Mix the infusion bag manually using a rocking motion.
Lymfødem, der forekom i behandlingsperioden, fortsatte i opfølgningsperioden hos 5 patienter (0,9 %) i TAC-armen og 2 patienter (0,4 %) i FAC-armen. 
Lymphoedema that started during the treatment period persisted into the follow-up period in 5 patients (0.9%) in TAC arm and 2 patients (0.4 %) in FAC arm. At the end of the follow-up period,
Dyspepsi; 
Dyspnoea;
• Injicer via en enkelt injektion (et stik) den nødvendige mængde Docetaxel Accord koncentrat til infusionsvæske, opløsning i en 250 ml infusionspose indeholdende enten en 5 % glucoseinfusionsvæske eller en 0,9 % natriumchloridinfusionsvæske. 
• Then, inject via a single injection (one shot) into a 250 ml infusion bag containing either 5% glucose solution or sodium chloride 9 mg/ml (0.9%) solution for infusion.
Den anbefalede dosis af docetaxel er 75 mg/m2 som en 1-times infusion, efterfulgt af cisplatin 75 mg/m2, som en 1-3-timers infusion (begge kun på dag 1), efterfulgt af 5-fluoruracil 750 mg/m2 pr. 
The recommended dose of docetaxel is 75 mg/m2 as a 1-hour infusion, followed by cisplatin 75 mg/m2, as a 1- to 3-hour infusion (both on day 1 only), followed by 5-fluorouracil 750 mg/m2 per day given as a 24-hour continuous infusion for 5 days, starting at the end of the cisplatin infusion.
Docetaxel Accord i kombination med cisplatin er indiceret til behandling af patienter med inoperabel lokalt fremskreden eller metastatisk ikke-småcellet lungekræft hos patienter, der ikke tidligere har fået kemoterapi mod denne tilstand. 
Docetaxel Accord in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer, in patients who have not previously received chemotherapy for this condition.
• operabel, lymfeknude-negativ brystkræft 
• operable node-negative breast cancer .
Synkope (G3/4: 0 %) Neurotoksicitet (G3/4: Døsighed (G3/4: 0 %) 
Syncope (G3/4: 0%); Neurotoxicity (G3/4: Somnolence (G3/4: 0%)
- Øvrige indholdsstoffer: polysorbat 80, vandfri ætanol (pkt. 
- The other ingredients are polysorbate 80, ethanol anhydrous (see section 2) and citric acid anhydrous.
Infusionsopløsningen må ikke være forbundet med infusionssættet i mere end 6 timer ved opbevaring ved 25°C. 
Do not couple the infusion solution to the infusion set for more than 6 hours when stored at 25°C.
Docetaxel Accord koncentrat til infusionsvæske, opløsning er en klar, lys gul til brunliggul opløsning. 
What Docetaxel Accord looks like and contents of the pack Docetaxel Accord concentrate for solution for infusion is a clear pale yellow to brownish-yellow solution.
Docetaxel Accord i kombination med capecitabin er indiceret til behandling af patienter med lokal fremskreden eller metastatisk brystkræft efter svigt af cytotoksisk kemoterapi. 
Docetaxel Accord in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy.
Patienter i docetaxel-armen fik docetaxel (T) 75 mg/m2 efterfulgt af cisplatin (P) 75 mg/m2 efterfulgt af 5-fluoruracil 750 mg/m2 
Patients on the docetaxel arm received docetaxel (T) 75 mg/m2 followed by cisplatin (P) 75 mg/m2 followed by 5-fluorouracil (F) 750 mg/m2 per day as a continuous infusion for 5 days.
Dette lægemiddel indeholder 50 % vol. vandfri ætanol (alkohol), dvs. op til 395 mg vandfri ætanol pr. hætteglas, svarende til 10 ml øl eller 4 ml vin. 
This medicinal product contains 50 vol % ethanol anhydrous (alcohol), i.e. up to 395 mg ethanol anhydrous per vial, equivalent to 10 ml of beer or 4 ml wine.
Tilfælde af elektrolytforstyrrelser er rapporteret. 
Metabolism and nutrition disorders Cases of electrolyte imbalance have been reported.
Indlægseddel: Information til brugeren Docetaxel Accord 20 mg/1 ml koncentrat til infusionsvæske, opløsning Docetaxel Accord 80 mg/4 ml koncentrat til infusionsvæske, opløsning Docetaxel Accord 160 mg/8 ml koncentrat til infusionsvæske, opløsning docetaxel 
NAME OF THE MEDICINAL PRODUCT Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion Docetaxel Accord 160 mg/8 ml concentrate for solution for infusion
• Til behandling af hoved- og hals-kræft indgives docetaxel i kombination med cisplatin og 5fluoruracil. 
- For the treatment of head and neck cancer, docetaxel is administered in combination with cisplatin and 5-fluorouracil.
Docetaxel Accord i kombination med trastuzumab er indiceret til behandling af patienter med metastatisk brystkræft, hvis tumorer overudtrykker HER2, og som ikke tidligere har fået kemoterapi mod metastatisk sygdom. 
Docetaxel Accord in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express HER2 and who previously have not received chemotherapy for metastatic disease.
Konstipation (alvorlig: 0,2 %); Mavesmerter (alvorlig: 1 %); 
Constipation (severe: 0.2%); Abdominal pain (severe: 1%); Gastrointestinal haemorrhage (severe: 0.3%)
For de patienter med serum-bilirubin > øvre normalværdi og/eller ALAT og ASAT > 3,5 gange øvre normalværdi og basiske fosfataser > 6 gange øvre normalværdi, kan det ikke anbefales at reducere dosis. 
For patients with serum bilirubin levels > ULN and/or ALT and AST > 3.5 times the ULN concurrent with serum alkaline phosphatase levels > 6 times the ULN, no dose-reduction can be recommended and docetaxel should not be used unless strictly indicated.
Der er udført to randomiserede, sammenlignende fase III-studier med docetaxel doseret hver 3. uge i den anbefalede dosis på 100 mg/m2 til patienter med metastatisk brystkræft. 
Two randomised phase III comparative studies, involving a total of 326 alkylating or 392 anthracycline failure metastatic breast cancer patients, have been performed with docetaxel at the recommended dose and regimen of 100 mg/m2 every 3 weeks.
LÆGEMIDLETS NAVN, STYRKE OG/ELLER ADMINISTRATIONSVEJ(E) Docetaxel Accord 20 mg/1 ml sterilt koncentrat docetaxel 
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Docetaxel Accord 20 mg/1 ml sterile concentrate docetaxel
Perifer sensorisk neuropati (G3: 4,1 %); Perifer motorisk neuropati (G3/4: 4 %) Dysgeusi (alvorlig: 
Peripheral sensory neuropathy (G3: 4.1%); Peripheral motor neuropathy (G3/4: 4%); Dysgeusia (severe: 0.07%)
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hver ml koncentrat indeholder 20 mg docetaxel. 
STATEMENT OF ACTIVE SUBSTANCE(S) Each ml of concentrate contains 20 mg docetaxel.
Docetaxel Accord 160 mg/8 ml koncentrat til infusionsvæske, opløsning 1 hætteglas på 8 ml koncentrat indeholder 160 mg docetaxel. 
Docetaxel Accord 160 mg/8 ml concentrate for solution for infusion One vial of 8 ml of concentrate contains 160 mg of docetaxel.
Medmindre det er kontraindiceret, kan der til brystkræft og ikke-småcellet lungekræft gives et peroralt kortikosteroid som præmedicinering, eksempelvis dexamethasone 16 mg per dag i 3 dage (f.eks. 8 mg 2 gange daglig). 
For breast, non-small cell lung, gastric, and head and neck cancers, premedication consisting of an oral corticosteroid, such as dexamethasone 16 mg per day (e.g. 8 mg twice daily) for 3 days starting 1 day prior to docetaxel administration, unless contraindicated, can be used (see section 4.4).
Konstipation (G3/4: 1,0 %); Gastrointestinale smerter (G3/4: Oesophagitis/dysfagi/odynofagi (G3/4: 0,7 %) 
Gastrointestinal pain (G3/4: Oesophagitis/dysphagia/odynop hagia (G3/4: 0.7%)
Docetaxel Accord er indiceret til behandling af patienter med lokalt fremskreden eller metastatisk ikke-småcellet lungekræft efter behandlingssvigt af kemoterapi. 
Docetaxel Accord is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy.
Docetaxel Accord 20 mg/1 ml koncentrat til infusionsvæske, opløsning 1 hætteglas på 1 ml koncentrat indeholder 20 mg docetaxel. 
Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion One vial of 1 ml of concentrate contains 20 mg of docetaxel.
Beskrivelse af udvalgte bivirkninger ved behandling af brystkræft med docetaxel 100 mg/m² i kombination med trastuzumab: 
Description of selected adverse reactions in breast cancer for docetaxel 100 mg/m2 in combination with trastuzumab
Du skal fortsætte med at tage præmedicinen i endnu 1 til 2 dage for at formindske visse bivirkninger, som kan forekomme efter infusionen af Docetaxel Accord. 
You will be asked to take premedication consisting of an oral corticosteroid such as dexamethasone, one day prior to Docetaxel Accord administration and to continue for one or two days after it in order to minimise certain undesirable effects which may occur after the infusion of Docetaxel Accord in particular allergic reactions and fluid retention (swelling of the hands, feet, legs or weight gain).
Hazard ratio (TAC/FAC) 
Hazard ratio (TAC/FAC) (95% CI)
Hos patienter, der behandles med docetaxel som enkeltstof i dosis på 100 mg/m2, som har en serumtransaminase-værdi (ALAT og/eller ASAT) på mere end 1,5 gange den øvre normalværdi samtidig med, at de serum-basiske fosfatase-værdier overstiger den øvre normalværdi 2,5 gange, er der en større risiko for udvikling af alvorlige bivirkninger. 
Patients with hepatic impairment Based on pharmacokinetic data with docetaxel at 100 mg/m2 as single agent, patients who have both elevations of transaminase (ALT and/or AST) greater than 1.5 times the upper limit of the normal range (ULN) and alkaline phosphatase greater than 2.5 times the ULN, the recommended dose of docetaxel is 75 mg/m2 (see sections 4.4 and 5.2).
Anvend ikke andre docetaxel-lægemidler bestående af 2 hætteglas (koncentrat og solvens) sammen med dette lægemiddel (Docetaxel Accord 160 mg/8 ml koncentrat til infusionsvæske, opløsning, som kun indeholder 1 hætteglas). 
DO NOT use other docetaxel medicines consisting of 2 vials (concentrate and solvent) with this medicine (Docetaxel Accord 160 mg/8 ml concentrate for solution for infusion, which contains only 1 vial).
• Hos patienter, der for anden gang udvikler grad 2-toksicitet eller første gang grad 3-toksicitet, skal behandlingen udsættes, indtil grad 0-1 nås. 
• For patients developing the second appearance of Grade 2 toxicity, or the first appearance of Grade 3 toxicity, at any time during the treatment cycle, delay treatment until resolved to Grade 0-1 and then resume treatment with docetaxel 55 mg/m2.
Beskrivelse af udvalgte bivirkninger ved behandling af gastrisk adenokarcinom med docetaxel 75 mg/m² i kombination med cisplatin og 5-fluoruracil: 
Description of selected adverse reactions in gastric adenocarcinoma cancer for docetaxel 75 mg/m2 in combination with cisplatin and 5-fluorouracil
Hyppigheden kan variere alt efter kombinationen af de lægemidler, du får. 
Between infusions of docetaxel the following may occur, and the frequency may vary with the combinations of medicines that are received
Docetaxel Accord 160 mg/8 ml koncentrat til infusionsvæske, opløsning Hvert hætteglas med koncentrat indeholder 4 ml vandfri ætanol (3,16 mg). 
Docetaxel Accord 160 mg/8 ml concentrate for solution for infusion Each vial of concentrate contains 4 ml of ethanol anhydrous (3.16 g).
For at kunne udtage den korrekte dosis til patienten, kan det være nødvendigt at anvende mere end et hætteglas Docetaxel Accord koncentrat til infusionsvæske, opløsning. 
More than one vial of Docetaxel Accord concentrate for solution for infusion may be necessary to obtain the required dose for the patient.
Et hætteglas på 8 ml koncentrat indeholder 160 mg docetaxel. 
One vial of 8 ml of concentrate contains 160 mg of docetaxel.
Docetaxel Accord i kombination med doxorubicin er indiceret til behandling af patienter med lokalt fremskreden eller metastatisk brystkræft, som ikke tidligere har fået kemoterapi mod denne tilstand. 
Docetaxel Accord in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.
Tabel over bivirkninger ved behandling af ikke-småcellet lungekræft med docetaxel 75 mg/m² i kombination med cisplatin: 
Tabulated list of adverse reactions in non-small cell lung cancer for docetaxel 75 mg/m2 in combination with cisplatin
Docetaxel Accord 20 mg/1 ml koncentrat til infusionsvæske, opløsning Klart glas (type I) hætteglas med fluorotec plus (ethylentetrafluoroethylenfilm) gummilukning og aluminiumforsegling og en orange afrivningshætte, indeholdende 1 ml koncentrat. 
Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion Clear glass (type I) vial with fluorotec plus (ethylene tetrafluoroethylene film) rubber stopper and aluminium seal and an orange flip-off cap, containing 1 ml of concentrate.
Bedste respons i alt til studie behandling [kemoterapi +/- strålebehandling] (%) (95 %CI) ***p-værdi 
Best overall response to study treatment [chemotherapy +/- radiotherapy] (%) (95% CI) ***p-value
Vaskulære sygdomme Hedeture (G3/4: 0,5%) Hypotension (G3/4: Flebitis (G3/4: 0 %) 
Hot flush (G3/4: 0.5%) Hypotension (G3/4: Phlebitis (G3/4: 0%)
Docetaxel Accord 160 mg/8 ml leveres i et 10 ml klart glashætteglas med fluorotec plus gummilukning og aluminiumforsegling og en rød afrivningshætte. 
Docetaxel Accord 160 mg/8 ml is supplied in a 10 ml clear glass vial with fluorotec plus rubber stopper and aluminium seal and a red flip-off cap.
Sikkerheden og effekten af docetaxel i den indledende behandling af patienter med lokalt fremskredent pladecellecarcinom i hoved og hals (SCCHN) blev evalueret i et randomiseret, multicenter, open-label fase III studie (TAX 324). 
• Induction chemotherapy followed by chemoradiotherapy (TAX324) The safety and efficacy of docetaxel in the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) was evaluated in a randomised, multicentre open-label, phase III study (TAX324).
Anvend ikke andre docetaxel-lægemidler bestående af 2 hætteglas (koncentrat og solvens) sammen med dette lægemiddel (Docetaxel Accord 20 mg/1 ml koncentrat til infusionsvæske, opløsning, som kun indeholder 1 hætteglas). 
DO NOT use other docetaxel medicines consisting of 2 vials (concentrate and solvent) with this medicine (Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion, which contains only 1 vial).
256 patienter blev randomiseret til behandling med docetaxel alene (100 mg/ m2 
256 patients were randomised to treatment with docetaxel alone (100 mg/m2 as a 1 hour intravenous infusion every 3 weeks).
Anvend ikke andre docetaxel-lægemidler bestående af 2 hætteglas (koncentrat og solvens) sammen med dette lægemiddel (Docetaxel Accord 80 mg/4 ml koncentrat til infusionsvæske, opløsning, som kun indeholder 1 hætteglas). 
DO NOT use other docetaxel medicines consisting of 2 vials (concentrate and solvent) with this medicine (Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion, which contains only 1 vial).
LÆGEMIDDELFORM OG INDHOLD (PAKNINGSSTØRRELSE) Koncentrat til infusionsvæske, opløsning. 
PHARMACEUTICAL FORM AND CONTENTS Concentrate for solution for infusion 1 vial
I de følgende tilfælde bør docetaxel-dosis reduceres til 65 mg/ m2 i de følgende behandlingsrunder: 1) hos patienter med en initialdosis på 75 mg/m2 docetaxel i kombination med cisplatin, med en minimum blodpladeværdi under den tidligere behandlingsrunde på < 25000 celler/mm3,2) hos patienter, der får febril neutropeni, 3) hos patienter, med alvorlig, ikke-hæmatologisk toksicitet. 
In combination with cisplatin For patients who are dosed initially at docetaxel 75 mg/m2 in combination with cisplatin and whose nadir of platelet count during the previous course of therapy is < 25,000 cells/mm3, or in patients who experience febrile neutropenia, or in patients with serious non-haematologic toxicities, the docetaxel dose in subsequent cycles should be reduced to 65 mg/m2.
Docetaxel Accord 80 mg/4 ml koncentrat til infusionsvæske, opløsning 1 hætteglas på 4 ml koncentrat indeholder 80 mg docetaxel. 
Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion One vial of 4 ml of concentrate contains 80 mg of docetaxel.
Docetaxel Accord 20 mg/1 ml leveres i et 5 ml klart glashætteglas med fluorotec plus gummilukning og aluminiumforsegling og en orange afrivningshætte. 
Docetaxel Accord 20 mg/1 ml is supplied in a 5 ml clear glass vial with fluorotec plus rubber stopper and aluminium seal and an orange flip-off cap.
LÆGEMIDLETS NAVN, STYRKE OG/ELLER ADMINISTRATIONSVEJ(E) Docetaxel Accord 160 mg/8 ml sterilt koncentrat docetaxel intravenøs anvendelse 
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Docetaxel Accord 160 mg/8 ml sterile concentrate docetaxel
Beskrivelse af udvalgte bivirkninger ved behandling af brystkræft for docetaxel 100 mg/m² enkeltstof 
Description of selected adverse reactions in breast cancer for docetaxel 100 mg/m2 single agent
Docetaxel Accord 80 mg/4 ml koncentrat til infusionsvæske, opløsning Klart glas (type I) hætteglas med fluorotec plus (ethylentetrafluoroethylenfilm) gummilukning og aluminiumforsegling og en rød afrivningshætte, indeholdende 4 ml koncentrat. 
Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion Clear glass (type I) vial with fluorotec plus (ethylene tetrafluoroethylene film) rubber stopper and aluminium seal and a red flip-off cap, containing 4 ml of concentrate.
Smerter i ekstremiteterne (G3/4: Rygsmerter (G3/4: 1 %); 
Pain in extremity (G3/4: < 1%); Back pain (G3/4: 1%)
Efter 10 års opfølgning i GEICAM9805-studiet forekom akut leukæmi hos 1 ud af 532 (0,2%) patienter i TAC-armen. 
After 10 years of follow-up in GEICAM 9805 study acute leukaemia occurred in 1 of 532 (0.2%) patients in TAC arm No cases were reported in patients in FAC arm No patient was diagnosed with myelodysplastic syndrome in either treatment groups.
I slutningen af opfølgningsperioden blev lymfødem observeret at være vedvarende hos 4 patienter (0,8 %) i TAC-armen og hos 1 patient (0,2 %) i FACarmen. 
lymphoedema was observed to be ongoing in 4 patients (0.8%) in TAC arm, and in 1 patient (0.2%) in FAC arm.
Docetaxel Accord 160 mg/8 ml indeholder 50 % vol. vandfri ætanol (alkohol), dvs. op til 3,16 g vandfri ætanol pr. hætteglas, svarende til 80 ml øl eller 33 ml vin. 
50 vol % ethanol anhydrous (alcohol), i.e. up to 3.16 g ethanol anhydrous per vial, equivalent to 80 ml of beer or 33 ml wine.
Docetaxel Accord 80 mg/4 ml indeholder 50 % vol. vandfri ætanol (alkohol), dvs. op til 1,58 g vandfri ætanol pr. hætteglas, svarende til 40 ml øl eller 17 ml vin. 
50 vol % ethanol anhydrous (alcohol), i.e. up to 1.58 g ethanol anhydrous per vial, equivalent to 40 ml of beer or 17 ml wine.
Tabel over bivirkninger ved behandling af ikke-småcellet lungekræft med docetaxel 75 mg/m² enkeltstof: 
Tabulated list of adverse reactions in non-small cell lung cancer for docetaxel 75 mg/m2 single agent
Docetaxel Accord 20 mg/1 ml koncentrat til infusionsvæske, opløsning docetaxel 
NAME OF THE MEDICINAL PRODUCT Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion docetaxel
Et hætteglas på 1 ml koncentrat indeholder 20 mg docetaxel. 
One vial of 1 ml of concentrate contains 20 mg of docetaxel.
LÆGEMIDLETS NAVN, STYRKE OG/ELLER ADMINISTRATIONSVEJ(E) Docetaxel Accord 80 mg/4 ml sterilt koncentrat docetaxel intravenøs anvendelse 
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Docetaxel Accord 80 mg/4 ml sterile concentrate docetaxel
Tabel over bivirkninger ved behandling af brystkræft med docetaxel 75 mg/m² i kombination med capecitabin: 
Tabulated list of adverse reactions in breast cancer for docetaxel 75 mg/m2 in combination with capecitabine
Docetaxel Accord 160 mg/8 ml koncentrat til infusionsvæske, opløsning docetaxel 
NAME OF THE MEDICINAL PRODUCT Docetaxel Accord 160 mg/8 ml concentrate for solution for infusion docetaxel
Koncentrationen af docetaxel i Docetaxel Accord 20 mg/1 ml er 20 mg/ml 
Docetaxel Accord 20 mg/1 ml contains
Luftveje, thorax og mediastinum Epistaxis; pharyngolaryngeal smerte; nasopharyngitis; dyspnø; hoste; næseflåd 
Epistaxis; Pharyngolaryngeal pain; Nasopharyngitis;
FREMSTILLINGSVEJLEDNING TIL BRUG VED DOCETAXEL ACCORD KONCENTRAT TIL INFUSIONSVÆSKE, OPLØSNING 
The following information is intended for healthcare professionals only: PREPARATION GUIDE FOR USE WITH DOCETAXEL ACCORD CONCENTRATE FOR SOLUTION FOR INFUSION
Et hætteglas på 4 ml koncentrat indeholder 80 mg docetaxel. 
One vial of 4 ml of concentrate contains 80 mg of docetaxel.